[go: up one dir, main page]

AR060829A1 - Metodo para el tratamiento del sindrome del intestino irritable con prodominio de diarrea - Google Patents

Metodo para el tratamiento del sindrome del intestino irritable con prodominio de diarrea

Info

Publication number
AR060829A1
AR060829A1 ARP070101888A ARP070101888A AR060829A1 AR 060829 A1 AR060829 A1 AR 060829A1 AR P070101888 A ARP070101888 A AR P070101888A AR P070101888 A ARP070101888 A AR P070101888A AR 060829 A1 AR060829 A1 AR 060829A1
Authority
AR
Argentina
Prior art keywords
inhibitor
sii
thioxo
methylene
treatment
Prior art date
Application number
ARP070101888A
Other languages
English (en)
Inventor
Barry D Quart
David P Rosenbaum
Thomas X Neenan
Robert C Blanks
Original Assignee
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38648619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR060829(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Napo Pharmaceuticals Inc filed Critical Napo Pharmaceuticals Inc
Publication of AR060829A1 publication Critical patent/AR060829A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Métodos para tratar el síndrome del intestino irritable con predominio de diarrea que consiste en administrar a un paciente que lo necesita un inhibidor del transporte de iones de cloruro en una cantidad suficiente para tratar el síndrome del intestino irritable con predominio de diarrea (d-SII). El tratamiento del d-SII incluye el tratamiento del componente diarrea del d-SII, así como también el dolor, el malestar abdominal y otros síntomas asociados al d-SII. En una realizacion, el inhibidor del transporte de iones de cloruro es crofelemer. Reivindicacion 5: El método de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizado porque el inhibidor es un extracto de Croton spp. o Calophyllum spp. Reivindicacion 8: El método de acuerdo con la reivindicacion 7, caracterizado porque el inhibidor de la funcion CFTR se selecciona entre el grupo que comprende compuesto de 2-tioxo-4-tiazolidinona y 3-[(3-trifluorometi)fenil]-5-[(3carboxifenil)metilen]-2-tioxo-4- tiazolidinona, tolbutamida, glibenclamida y fluoresceína o un derivado de ellas, diazoxido, lemakalim, sulfato de minoxidil y sus análogos; 8- bromo-cAMP, 8-(4-clorofeniltio) (CPT)-cAMP y 8-bromo-cGMP, CPT-cGMP; verapamil, nifeldipidina, diltiazem, compuestos de estilbeno disulfonicos, difenilamina-2-carboxilato (DPC) o 5-nitro-2(3-fenilpropilamino)benzoato (NPPB); ácido antraceno-9-carboxílico (9-AC); 3-[(3-trifluorometi)fenil]-5-[(3-carboxifenil)metilen]-2-tioxo-4-tiazolidinona; N-(2- naftalenil)-[3,5-dibromo-2,4-dihidroxifenil)metilen]glicina hidrazida (GlyH-101) o sus derivados; dihydrazidas del ácido malonico o sus derivados; loperamida; racecadotril; clorhidrato de lidamidina; lonidamina; vanadato; bumetamida; pp2a; PP1; PP2B, subsalicilato de bismuto; clorhidrato de difenoxilato; y esparteína. Reivindicacion 9: El método de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizado porque el inhibidor es una composicion polimérica sintética o de origen natural. Reivindicacion 10: El método de acuerdo con la reivindicacion 9, caracterizado porque la composicion polimérica comprende al menos un monomero seleccionado entre el grupo que comprende catequina, epicatequina, galocatequina y epigalocatequina. Reivindicacion 11: El método de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizado porque el inhibidor es una composicion polimérica de proantocianidina.
ARP070101888A 2006-05-01 2007-05-02 Metodo para el tratamiento del sindrome del intestino irritable con prodominio de diarrea AR060829A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79707406P 2006-05-01 2006-05-01
US11/510,152 US20070254050A1 (en) 2006-05-01 2006-08-24 Method for treatment of diarrhea-predominant irritable bowel syndrome

Publications (1)

Publication Number Publication Date
AR060829A1 true AR060829A1 (es) 2008-07-16

Family

ID=38648619

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101888A AR060829A1 (es) 2006-05-01 2007-05-02 Metodo para el tratamiento del sindrome del intestino irritable con prodominio de diarrea

Country Status (18)

Country Link
US (3) US20070254050A1 (es)
EP (1) EP2034844B1 (es)
JP (2) JP5384329B2 (es)
KR (2) KR101487919B1 (es)
AR (1) AR060829A1 (es)
AU (1) AU2007248172B2 (es)
CA (1) CA2650294C (es)
DK (1) DK2034844T3 (es)
ES (1) ES2628290T3 (es)
MX (2) MX2008013871A (es)
NZ (2) NZ609344A (es)
PE (1) PE20081569A1 (es)
PL (1) PL2034844T3 (es)
PT (1) PT2034844T (es)
SG (1) SG174025A1 (es)
TR (1) TR201708043T4 (es)
TW (2) TWI481410B (es)
WO (1) WO2007130882A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP2061327B1 (en) * 2006-05-01 2016-10-05 Napo Pharmaceuticals, Inc. Compositions for treating or preventing inflammatory bowel disease
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
DK2241318T3 (da) 2006-05-01 2013-01-21 Napo Pharmaceuticals Inc Fremgangsmåde til behandling af irritabelt tyktarmssyndrom med fremherskende forstoppelse
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
EP2719380A3 (en) * 2008-09-16 2014-07-30 University of Maryland, Baltimore SUR1 inhibitors for therapy
JP4565219B2 (ja) * 2008-12-26 2010-10-20 アサヒビール株式会社 ポリフェノール含有顆粒またはポリフェノール含有チュアブル錠剤およびその製造方法
EP2485596A4 (en) * 2009-10-06 2013-07-17 Univ California METHOD FOR THE TREATMENT OF DISEASES WITH PROANTHOCYANIDINOLIGOMERS SUCH AS CROFELEMER
WO2011073950A1 (en) * 2009-12-17 2011-06-23 National University Of Singapore Method of preparing derivatives/oligomers of epicatechin and applications thereof
AU2011320155B2 (en) * 2010-10-31 2016-02-25 Napo Pharmaceuticals, Inc. Methods and compositions for treating HIV-associated diarrhea
WO2012135702A1 (en) * 2011-04-01 2012-10-04 Ocean Spray Cranberries, Inc. Inflammation and immunity treatments
EP2701715A4 (en) * 2011-04-27 2015-06-03 Univ Northshore Healthsystem PROPHYLAXIS AND TREATMENT OF ENTEROPATHOGENIC BACTERIAL INFECTIONS
WO2013161973A1 (en) * 2012-04-23 2013-10-31 Sucampo Ag Method for treating irritable bowel syndrome with diarrhea
MX369122B (es) * 2012-11-21 2019-10-30 Kbs Res Llc Suplementos herbales y métodos para utilizar los mismos.
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
KR101579688B1 (ko) 2014-07-08 2015-12-24 재단법인 전남생물산업진흥원 좁쌀풀 추출물을 유효성분으로 함유하는 과민성 대장증후군에 의한 내장 통증 억제예방 또는 치료용 약학 조성물
CN104873485B (zh) * 2015-05-08 2019-02-19 中国药科大学 槲皮素治疗与胃肠道应激失调相关疾病的用途
CN107125440A (zh) * 2016-02-29 2017-09-05 湖南晶天科技实业有限公司 一种饲料添加剂肠溶包衣单宁酸及其制备方法以及一种饲料
IT201600122310A1 (it) 2016-12-01 2018-06-01 Sofar Spa Composizione per uso nella terapia di alterazioni dell'intestino
US20180185356A1 (en) 2016-12-23 2018-07-05 Maregade Rx, LLC Low dose product and method for treating diarrhea
EP3592333B1 (en) * 2017-03-06 2024-04-03 Athena Pharmaceutiques SAS A pharmaceutical composition comprising racecadotril and process for preparing the same
JOP20190275A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
US20220280514A1 (en) * 2019-06-12 2022-09-08 The Regents Of The University Of California Methods of treating bile acid diarrhea
CN113975412B (zh) * 2021-12-30 2022-04-05 北京赛尔富森生物科技有限公司 一种评价轮状病毒疫苗有效性的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE446940B (sv) 1983-02-16 1986-10-20 Carl Axel Virdalm Medel for bekempande av sjukdomstillstand i matsmeltningsapparaten innehallande skal eller ytterdelar av ber eller frukter
US4698360B1 (en) 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
EP0214317B1 (fr) 1985-08-30 1988-08-17 Societe Des Produits Nestle S.A. Produit diététique à activité dépurative et anti-diarrhéique et son procédé de préparation
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
SI9011933A (sl) 1990-10-15 1998-06-30 TANIN SEVNICA Kemična industrija p.o. Kostanjev taninski ekstrakt, postopek za njegovo pridobivanje in njegova uporaba
US5234922A (en) 1992-09-28 1993-08-10 University Of Iowa Research Foundation Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea
FI962667L (fi) 1996-06-27 1997-12-28 Scanwoven Ab Oy Kuitutuote, menetelmä ja laitteisto kuitutuotteen valmistamiseksi
DE69739394D1 (de) 1996-10-16 2009-06-18 Napo Pharmaceuticals Inc Enteral-formulierungen von proanthocyanidzusammensetzungen gegen diarrhöe
AU6967198A (en) 1997-04-10 1998-10-30 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US20040063695A1 (en) 2002-09-30 2004-04-01 Alan Verkman Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7208183B2 (en) * 2002-10-05 2007-04-24 Bobrowski Paul J Methods and preparations of the latex from the croton species
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
EP2061327B1 (en) 2006-05-01 2016-10-05 Napo Pharmaceuticals, Inc. Compositions for treating or preventing inflammatory bowel disease
DK2241318T3 (da) 2006-05-01 2013-01-21 Napo Pharmaceuticals Inc Fremgangsmåde til behandling af irritabelt tyktarmssyndrom med fremherskende forstoppelse
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
EP2485596A4 (en) 2009-10-06 2013-07-17 Univ California METHOD FOR THE TREATMENT OF DISEASES WITH PROANTHOCYANIDINOLIGOMERS SUCH AS CROFELEMER
AU2011320155B2 (en) 2010-10-31 2016-02-25 Napo Pharmaceuticals, Inc. Methods and compositions for treating HIV-associated diarrhea
MX2015007065A (es) 2012-12-07 2017-03-01 Napo Pharmaceuticals Inc Metodo y composiciones para tratar diarrea asociada con vih.

Also Published As

Publication number Publication date
KR101537361B1 (ko) 2015-07-17
PT2034844T (pt) 2017-06-26
MX382400B (es) 2025-03-13
AU2007248172A1 (en) 2007-11-15
US8846113B2 (en) 2014-09-30
MX2008013871A (es) 2009-01-07
TW200810772A (en) 2008-03-01
TW201434475A (zh) 2014-09-16
US20120189720A1 (en) 2012-07-26
JP5820440B2 (ja) 2015-11-24
SG174025A1 (en) 2011-09-29
JP5384329B2 (ja) 2014-01-08
US9980938B2 (en) 2018-05-29
KR101487919B1 (ko) 2015-02-03
CA2650294C (en) 2019-01-22
US20070254050A1 (en) 2007-11-01
KR20090009291A (ko) 2009-01-22
NZ595749A (en) 2013-11-29
KR20130063552A (ko) 2013-06-14
DK2034844T3 (en) 2017-06-06
EP2034844A2 (en) 2009-03-18
TR201708043T4 (tr) 2018-11-21
ES2628290T3 (es) 2017-08-02
AU2007248172B2 (en) 2013-03-21
WO2007130882A2 (en) 2007-11-15
JP2014012695A (ja) 2014-01-23
JP2009535417A (ja) 2009-10-01
TWI574694B (zh) 2017-03-21
PL2034844T3 (pl) 2017-09-29
WO2007130882A3 (en) 2008-02-07
NZ609344A (en) 2014-08-29
US20150050338A1 (en) 2015-02-19
EP2034844A4 (en) 2010-11-17
CA2650294A1 (en) 2007-11-15
EP2034844B1 (en) 2017-03-22
PE20081569A1 (es) 2009-01-14
TWI481410B (zh) 2015-04-21

Similar Documents

Publication Publication Date Title
AR060829A1 (es) Metodo para el tratamiento del sindrome del intestino irritable con prodominio de diarrea
BRPI0514357A (pt) combinações para o tratamento de doenças que envolvem a proliferação de células
JP2009535417A5 (es)
BRPI0519700A2 (pt) misturas fungicidas, agente, processo para combater fungos nocivos fitopatogênicos, semente, uso dos compostos
CU20090209A7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
CR7877A (es) Derivados de 4-tetrazolil-4-fenilpiperidina para tratar el dolor
EA200901443A1 (ru) Фунгицидные смеси
MA31094B1 (fr) Utilisation de dérivés de pyranone-acide substituée pour le traitement du syndrome métabolique
CR10943A (es) Mezclas fungicidas a partir de 1-metilpirazol- 4- ilcarboxanilidas y azolopirimidinilaminas
BRPI0519698A2 (pt) misturas fungicidas, agente, processo para combater fungos nocivos fitopatogênicos, semente, e, uso dos compostos
BRPI0519234A2 (pt) misturas fungicidas para combater fungos nocivos fitopatogÊnicos, agente, processo para combater fungos nocivos fitopatogÊnicos, sementes, e, uso dos compostos
BRPI0515261A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo
BRPI0519236A2 (pt) misturas fungicidas, agente, processo para combater fungos nocivos fitopatogÊnicos, semente, e, uso dos compostos
KR970701044A (ko) 콜린에스테라제 활성제
BRPI0407271A (pt) Composição anti-helmìntica
ES2497766T3 (es) Composiciones y procedimientos de sensibilizar a oxacilina Staphylococcus aureus resistente a meticilina
EA200800788A1 (ru) Фунгицидные смеси на основе триазолов
NO20022000L (no) 6-metoksy-2-naftyleddiksyre-prodrogesammensetninger til behandling av inflammasjon
CR9316A (es) Derivados de amida como ligando de canales ionicos y composiciones farmaceuticas y metodos para usar los mismos
BRPI0519230A2 (pt) misturas fungicidas, agente, processo para combater fungos nocivos fitopatogÊnicos, semente, e, uso dos compostos
MX2010007956A (es) Analogos de 13,13-dimetil-des-c,d de compuestos de 1a,25-dihidroxi-19-nor-vitamina d3 y formas de dosificacion de composicion topica y metodos de tratamiento de condiciones de la piel.
AR018808A1 (es) Mezclas fungicidas y el procedimiento para combatir hongos nocivos con dichas mezclas
ECSP066704A (es) Mezclas fungicidas
WO2007058639A3 (en) Antibacterial agents
CO5050348A1 (es) Mezclas fungicidas que contienen fenil-bencil eteres y carboxamidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure